This article was originally published in The Rose Sheet
Research Institute for Fragrance Materials "strives to be the international leader for the safe use of fragrance ingredients, and has ongoing research programs in the areas of fragrance allergy, human health effects, respiratory safety and environmental impact," President Ladd Smith states in a letter to the editor of Environmental Health Perspectives published in the November issue of the journal. Smith responds to letter on the toxicity of fragrances by Luke Curtis of the University of Illinois School of Public Health published in June stating the need for more research on the health effects of artificial flavors and fragrances. Vast majority of 4,000 chemicals used in artificial fragrances have not been tested for human toxicity, according to Curtis. Smith, however, points to more recent studies on fragrances and notes RIFM's research is modeled after the National Academy of Sciences' risk assessment method and that research results and safety evaluations are published in peer-reviewed journals...
You may also be interested in...
Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in a few regions. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India till deal ends and non-exclusive rights for developing countries till pandemic lasts, with Novavax getting half of net revenue.
The market for heart failure diagnostics and devices is set to grow by 3.8% annually in the next three years, with emerging markets leading the growth, according to the new Meddevicetracker Dashboard.
Perrigo management provided colorful commentary on Perrigo’s latest endeavors to separate the company’s US generics business, following the recent sale of Perrigo’s Rosemont Pharmaceuticals subsidiary for an “attractive” multiple.